MyMD Pharmaceuticals is a clinical stage pharmaceutical company. Co. is focused on developing and commercializing two therapeutic platforms based on therapeutic targets, MYMD-1 and Supera-CBD. MYMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune disease, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease and is being developed to treat age-related illnesses. Supera-CBD is a synthetic analog of cannabidiol being developed to treat various conditions, including epilepsy, pain and anxiety/depression, through its effects on the CB2 receptor, opioid receptors and monoamine oxidase enzyme type B. We show 14 historical shares outstanding datapoints in our coverage of MYMD's shares outstanding history.
Understanding the changing numbers of MYMD shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like MYMD versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching MYMD by allowing them to research MYMD shares outstanding history
as well as any other stock in our coverage universe. |
Free MYMD Email Alerts:
Video: Shares Outstanding Importance
